Company* | Company* | Type/Product Area | Terms/Details (Date) |
| | |||
4SC AG | Wilex AG | Research collaboration to optimize and synthesize second-generation inhibitors of urokinase, a protein known to play a role in tumor metastasis | 4SC will build and screen virtual combinatorial libraries for candidate compounds based on WX-293; in return, 4SC will receive research funding and milestone payments (1/14) |
Acadia Pharm- | Amgen Inc. | Agreement to discover small-molecule drugs based on genomics targets | The deal is potentially worth $20M; Amgen gains the right to develop and commercialize drugs directed at each of the genomic targets; Acadia will receive research funding and milestones (1/4) |
Access | Gem Pharma- | Licensing agreement for GPX-100 and GPX-150 | Access will fund all future development, plus make up-front payments and pay development milestones of up to $33M, as well as royalties on sales of approved products; Access gains exclusive licensing rights in all markets of the world with the exception of Asia (1/10) |
Actelion Ltd. | Berna | Clinical development partnership between Berna and Hesperion Ltd., an independent company in which Actelion owns a controlling majority | The companies will pool resources and form the Center of Excellence for Vaccine Development (3/13) |
Agilon | PrimeGen | Agreement to expand and strengthen PrimeGen's property in the stem cell and genetic research space | Companies also will accelerate the acceptance of PrimeGen's Cellular Replacement Therapy (3/11) |
Albany | Myriad | Multiyear agreement to conduct chemistry research and development in undisclosed therapeutic areas | AMRI will prepare compounds for biological screening by Myriad, with the goal of identifying and developing novel therapeutics; the first project will continue for up to one year (1/30) |
Albany | Nobex | Collaborative research program to develop a library of Nobex polymers for use in pharmaceuticals and also in the life sciences, cosmetics, food and industrial sectors | Albancy Molecular will provide Nobex with a library of more than 500 combinations of water- and fat-soluble polymers that can provide delivery advantages to pharmaceutical products (3/4) |
Allergan Inc. | EntreMed | Agreement to develop and commercialize Panzem, an angiogenic inhibitor | The five-year deal is potentially worth $40M; Allergan gains an exclusive worldwide license to commercialize Panzem for ophthalmic uses (1/23) |
Altachem | Undisclosed | Agreement in which Altachem acquired an immunomodulator with anticancer properties | Altachem will issue from treasury 400,000 common shares to the undisclosed party for the compound, subject to certain development milestones being met and the receipt of stock exchange and regulatory approvals (3/18) |
Anadys Pharm- | Structural | Partnership to discover small-molecule antibacterial drugs, and a second agreement allowing Structural GenomiX to use Atlas to screen for internal drug discovery efforts | The companies will share equally in the costs of the first agreement; in the second agreement, Anadys will receive an up-front technology access payment, research funding and potential milestones (2/20) |
Antares | MacroMed | Technology and business development collaboration to optimize MacroMed's ReGel sustained-release gel technology for use with Antares' needle-free and mini-needle injection technologies | The goal will be to develop a depot drug delivery system that releases medication from a subcutaneous injection site reservoir over a two-, four- or six-week period (3/19) |
ApoImmune | Large Scale | Alliance involving the production of therapeutic proteins related to stimulating the human immune system | LSBC expects to produce two of ApoImmune's polypeptides (3/22) |
Applied | Chiron Corp. | Collaboration to optimize a nonantibody protein that Chiron will focus on developing as a human therapeutic | Applied Molecular will receive an upfront signing fee, potential milestone payments and royalties on any product sales (1/3) |
Array | Amgen Inc. | Drug discovery agreement replacing the previous PTP-1B collaboration announced in November 2000 | Array will retain all rights to the existing PTP-1B program; Amgen will pay fees to Array, as well as success-based milestone payments (1/14) |
Artesian | Gene Logic | Subscription agreement to Gene Logic's GeneExpress Cardiovascular DataSuite for use as a primary reference source in Artesian's drug discovery and development efforts in cardiovascular disease | Financial details of the multiyear agreement were not disclosed (3/14) |
Atugen AG | Kinetek | Technology evaluation agreement focused on the discovery and development of selective signal transduction inhibitors in cancer and inflammatory diseases | Kinetek will evaluate the application of Atugen's target-validation technology in its research and development efforts in oncology; Atugen will optimize its GeneBloc and cellular delivery technologies, and Kinetek will use the optimized molecules to validate the gene function of these targets (2/20) |
Automated | Abgenix Inc. | Agreement to apply Automated Cell's functional proteomics platform to Abgenix-initiated projects involving both therapeutic antibody candidates and novel protein targets for antibody therapy | The Automated Cell platform provides high-throughput target validation in oncology and immunology (2/12) |
Beyond | DiaDexus | Agreement in which Beyond Genomics will use its Systems Biology approach to identify biomarkers and drug targets for the treatment and diagnosis of colon, breast and ovarian cancer | DiaDexus made an equity investment in BG and will provide research funding for the program; the agreement provides milestone and royalty payments on products resulting from the research (2/19) |
Beyond | Micromass UK | Partnership under which Micromass will supply its mass spectrometry technologies to Beyond Genomics for use in its Systems Biology drug discovery platform | Waters will make an equity investment in Beyond Genomics; Micromass will have the opportunity to license certain Beyond Genomics intellectual property; also, Beyond Genomics may purchase Micromass products (2/22) |
BioDiscovery | Genops Bio- | Strategic collaboration to integrate BioDiscovery's GeneDirector with Genops' Ngene software and Linux cluster platform for high-throughput sequence analysis and annotation | The collaboration will result in a seamless product for integrated gene expression analysis (2/27) |
Biogen Inc. | Genaissance | Agreement in which the companies will apply Genaissance's HAP technology to Biogen's development-stage drugs and targets | Genaissance will receive an up-front cash payment, research funding and milestone payments, and it will process Biogen's clinical trial samples; Genaissance will receive downstream payments (2/1) |
Bioglan | Quintiles Trans- | Agreement in which Quintiles acquired certain assets of Bioglan Pharma Inc., a subsidiary of Bioglan Pharma | The transaction is valued at about $26.7M; Quintiles also acquired Bioglan Pharma's rights to certain dermatology products now on the U.S. market, including the prescription product Adoxa (doxycycline) for the treatment of severe acne (3/22) |
BioImage | Lexicon | Collaboration to identify small molecules that address selected proprietary drug targets from Lexicon's pipeline of in vivo validated targets | Lexicon will provide validated drug targets, as well as compound libraries and medicinal chemistry expertise (1/28) |
BioInvent | Oxford Glyco- | Three-year collaboration to identify, develop, manufacture and commercialize therapeutic antibodies | OGS will provide at least five target antigens per year; BioInvent will apply its n-CoDeR phage display library to identify antibodies targeted to OGS's antigens; BioInvent also will manufacture material; OGS will contribute research funding and will pay a technology access fee to BioInvent, which also may receive milestone and royalty payments; OGS also will make an equity investment of $5M in BioInvent (3/14) |
Biosite Inc. | Amgen Inc. | Multiyear agreement in which Biosite will use Omniclonal phage display technology, and potentially Trans-Phage Technology, to generate high-affinity antibodies to targets provided by Amgen | Amgen will provide targets for up to three years; Biosite will receive development fees, and may receive annual maintenance fees; it also could receive milestone and royalty payments, and will retain rights to certain targets (3/11) |
Bioxel Pharma | PolyGene Ltd. | Agreement to collaborate in the development of paclitaxel-based polymer implants for treating solid tumors | The trials will target tumors of the head and neck, brain, colon and prostate and sarcomas (3/20) |
British Biotech | MethylGene | Agreement for a potential $16.5M collaboration, giving British Biotech rights in Europe to develop and commercialize MethylGene's anticancer drug, MG98 | British Biotech will make $1.7M in research and development payments to MethylGene, which will have a shot at $12.8M in milestone payments; British Biotech also will make an equity investment of $2M in MethylGene, which also will receive undisclosed royalties on product sales (2/12) |
Cambridge | Amrad Corp. | Product development collaboration focused on the joint discovery and development of human antibody-based therapeutics that neutralize the receptor for granulocyte macrophage-colony stimulating factor | The companies will fund all development jointly through Phase II; CAT then has responsibility for further development and commercialization; Amrad has the option to receive milestone and royalty payments or to participate jointly in further development and commercialization (12/19) |
Cambridge | Immunex | Agreement for the development and commercialization of human monoclonal antibodies | Immunex exercised an exclusive license option giving it the right to develop human monoclonal antibodies specifically for an undisclosed disease target; CAT received a license fee and will potentially receive milestone and royalty payments (1/8) |
Celera | Oxagen Ltd. | Multiyear subscription agreement to Celera's genomic databases | Financial terms were not disclosed (1/18) |
Cellomics | Norak Bio- | Cross-license agreement granting Norak nonexclusive rights to Cellomics' intellectual property for high-content screening | Cellomics gains rights to Norak's intellectual property for Transfluor to facilitate the development and commercialization of software (12/18) |
Cepheid Inc. | Northrop | Collaboration on the adaptation of DNA-based biothreat detection technology | The technology will be used in the U.S. Postal Service mail sorting system (3/11) |
Cetek Corp.* | Tularik Inc. | Agreement to develop assays and perform high-throughput screens for the discovery of lead compounds | Financial terms were not disclosed (2/6) |
Clinomics | Viventia Bio- | Agreement for Clinomics to supply tissue microarray systems for Viventia's ImmunoMine screening program | Clinomics' network of consulting pathologists will provide interpretation of the cellular binding profile of selected Viventia antibodies discovered through its Hybridomics discovery platform (3/13) |
ComGenex | Echelon | Alliance aimed at cancer, and heart and inflammatory diseases | ComGenex will provide drug discovery chemistry capabilities, including high-throughput synthesis, analysis, ADME/Tox predictions, chemoinformatics and chemogenomics technologies (2/1) |
Commonwealth | Insmed Inc. | Contract research agreement to conduct out-sourced research and development and GLP-rated studies in support of Insmed's portfolio | Commonwealth will realize about $600,000 in gross revenues over a 24-month period; upon execution of the agreement, Commonwealth received $139,000 (3/12) |
Compugen | DiaDexus | Agreement to accelerate DiaDexus' ability to identify and validate diagnostic markers and therapeutic targets based on Compugen's computational biology analysis of genomic and proteomic databases | DiaDexus will use Compugen's LEADS computational biology platform and related tools to perform analysis of both proprietary and public genomic and proteomic databases; DiaDexus will use the results to develop human diagnostic and therapeutic products; Compugen will receive cash payments and a warrant to purchase equity in DiaDexus (1/16) |
Compugen | Millennium Pharmaceuticals Inc. (MLNM) | Agreement to co-develop software tools to assist in the prediction of protein pathways for use in drug discovery and development | The companies will share costs of the project and the rights to certain aspects of the technology developed (3/20) |
ConjuChem | Trimeris Inc. | Agreement for an exclusive right to negotiate for a worldwide license to ConjuChem's Drug Affinity Complex technology to create long-lasting HIV compounds | Trimeris paid an undisclosed up-front fee for the exclusive negotiating rights (12/26) |
Crucell NV (the Netherlands; CRXL) | Innogenetics | Nonexclusive license agreement for the manufacture of monoclonal antibody products on Crucell's human cell line, PER.C6 | Innogenetics will use the PER.C6 platform to develop monoclonal antibodies in the context of its therapeutic programs, and will be able to manufacture and market the emerging therapeutic products; Crucell will receive up-front and annual payments, as well as royalties (1/23) |
Crucell NV (the Netherlands; | Lexigen | Nonexclusive licensing agreement for Crucell's human cell system, PER.C6 | Lexigen will use the system for research and development of therapeutics in oncology; Crucell will receive up-front and annual payments, while Lexigen has an option for a commercial license (1/15) |
CuraGen Corp. | Alexion Pharm- | Multiyear drug target and validation agreement focused on oncology products | The initial focus will be cancer, but the collaboration could be expanded to other indications; CuraGen will retain rights to potential non-antibody protein therapeutics across all disease areas; Alexion will own the rights to develop and commercialize all antibody and small-molecule therapeutics; CuraGen will be eligible to receive licensing fees, development milestone payments and sales royalties (3/12) |
CuraGen Corp. | Sequenom Inc. | Collaboration to determine the biological context of disease-associated genes by using each other's respective population genetics and proteomics technologies | Sequenom will identify high-impact genes associated with human diseases using its population genetics approach; CuraGen will apply its platform of proteomic technologies; CuraGen also will enhance its own targets using Sequenom's single nucleotide polymorphism technologies and population genetics approach (3/13) |
Curis Inc. | AGY Therapeutics Inc.* | Collaboration to develop novel small-molecule drugs from stem cells for therapeutics, diagnostics and other applications relevant to neurodegenerative disease, diabetes, oncology and central nervous system diseases | Curis will share its stem cell and developmental biology expertise with AGY, which will apply its imAGYne technology platform to identify, analyze and validate novel small-molecule targets (1/17) |
Diversa Corp. | Degussa AG | Agreement to evaluate selected biocatalysts for specialty chemicals and pharmaceutical fine-chemical applications | Degussa will pay an initial fee to access Diversa's biocatalysts, as well as additional fees associated with the development; Degussa also will pay license fees and royalties (1/3) |
DNAPrint | GenoMed | Commercial and equity-based agreement in which Geno Med purchased a beta version of of an Orchid ultra-high-throughput genotyping system and has integrated it with DNAPrint's existing Orchid 25K SNPstream platform | The initial term of the contract is two years; the contract calls for DNAPrint to produce more than 4M genotypes for GenoMed in the first year at a cost of about $1.6M; DNA-Print also obtained a royalty stake in future GenoMed profitability (3/6) |
Enzon Inc. (ENZN) | Inhale | Agreement to jointly develop three products to be specified over time based on Inhale's Inhance pulmonary delivery platform and SEDS supercritical fluids platform, focusing on developing oncology products | Enzon will be responsible for the commercialization and clinical development, while Inhale will develop and manufacture resulting products; Enzon will purchase $40M of newly issued Inhale convertible preferred stock (1/8) |
Eos Biotech- | Pharmacopeia | Agreement giving Pharmacopeia Eos' therapeutic antibody target, allowing it to initiate high-throughput screening to identify small-molecule drug candidates | The companies will jointly own any arising compounds (1/8) |
Epimmune | Rhein Biotech | Research agreement under which Epimmune's Padre technology will be evaluated in connection with technology from Rhein Biotech for the development of certain vaccines | Epimmune and Rhein will evaluate the combination of their technologies to determine potential efficacy in several vaccines (1/9) |
Evotec OAI | SiReen AG | Drug discovery and development agreement to identify and synthesize small-molecule therapeutics | Evotec will perform assay development, screening and chemical synthesis for up to four targets over the next three years; SiReen will pay service fees to Evotec, which will receive an equity stake in SiReen; both companies will receive milestone and royalty payments for services provided (3/25) |
Exelixis Inc. | Cytokinetics | Collaboration to design and generate diverse, small-molecule compound libraries that each company will use to further advance its own drug discovery programs | Exelixis will use its combinatorial chemistry platform to synthesize compounds designed by the two companies; the compounds will be jointly owned; Exelixis will receive cash payments for compounds it delivers (1/4) |
Galapagos | Exelixis Inc. | Research collaboration to use Galapagos' adenoviral technology to analyze the function of novel genes in cell-based assays | Galapagos will construct recombinant adenoviruses harboring genes selected by Exelixis, which will use them to introduce the genes in various cell types to evaluate the function of the proteins encoded by the genes within targeted, disease-relevant biological pathways (1/23) |
Gemin X Bio- | Tranzyme | Collaboration in which Gemin X will provide Tranzyme with a gene to validate in hopes of finding new treatments for neurological disorders | Both companies are putting up their own technologies and combining resources (2/13) |
Gene Logic | Compugen Ltd. | Joint collaboration to integrate Compugen's human Gencarta annotated genomic and proteomic database with the gene expression information in Gene Logic's GeneExpress Suite | Financial terms were not disclosed (1/8) |
Gene Logic | Morphochem | Subscription agreement giving Morphochem access to Gene Logic's GeneExpress Oncology Datasuite | Morphochem also signed on to purchase a series of GeneExpress Reports; the agreement also called for data to be generated by Gene Logic from samples provided by Morphochem (2/19) |
Genencor | Agilent Tech- | Licensing agreement for the Rosetta Resolver Gene Expression Data Analysis System | The system is a data storage, retrieval and analysis solution for gene expression data; financial details were not disclosed (3/11) |
Genencor | Seattle Genetics | Multiyear agreement to discover and develop cancer therapeutics based on tumor-targeted enzymes that activate prodrugs | SGN-17/19 probably will be the first drug to benefit from the collaboration; the companies will share development costs and each will have the right to commercialize any resulting products within the field; Genencor will make a $3M equity investment in Seattle Genetics and will pay specific milestone payments and fees; Seattle Genetics also will make certain milestone payments to Genencor (1/7) |
GeneProt Inc.* | LION bioscience AG (Germany; LEON) | Three-year strategic and marketing collaboration for an integrated offering combining their core competencies to accelerate the drug discovery and development process | GeneProt will license LION's integration platform consisting of SRS and Discovery-Center software and selected LION scientific applications and will purchase related services from LION for up to $4.95M (3/14) |
GeneProt | Zymark | Agreement under which Zymark is named an exclusive automation provider to GeneProt in the U.S. and Europe | Zymark will make an undisclosed equity investment in GeneProt; GeneProt also granted Zymark nonexclusive licensed access to specific research discovery content for Zymark's internal use (3/4) |
Genetastix | Hyseq Pharma- | Agreement to generate fully human monoclonal antibodies against a proprietary antigen | Genetastix gets up-front money, plus research and development payments, in exchange for an option that lets Hyseq enter into an exclusive commercial use agreement for the antibodies; Genetastix also could collect more research and devleoment payments, plus license fees, milestones and royalties (2/13) |
Genicon | BD Biosciences | Agreement to design resonance light-scattering signal generation and detection technology for use with BD Biosciences Clontech's line of BD Atlas Microarrays | The companies hope to provide scientists with a means to detect differential gene expression as compared to commonly used fluorescent-based detection methods (12/18) |
Genmab A/S | Bionomics | Collaboration to create and develop fully human antibodies to angiogenesis targets identified by Bionomics | The companies will share equally in the research and development costs and the commercial rights and returns from antibody products they co-develop; the research will focus initially on two angiogenesis targets identified and patented by Bionomics (3/12) |
Genmab A/S | Oxford Glyco- | Collaboration combining targets discovered by way of OGS's proteomics platform with the combined capabilities of Medarex and Genmab | The deal is a 50-25-25 arrangement (1/9) |
Genomic | Proteometrics | Exclusive worldwide software license agreement | Genomic Solutions obtained the exclusive right to develop, support and license the Proteometrics bioinformatics product line (2/11) |
Gentris | Nanogen | Development site collaboration under which Nanogen will provide its NanoChip Molecular Biology Workstation to Gentris | Gentris will use the technology with its current applications to develop one or more commercially viable SNP assays; Nanogen will have exclusive commercialization rights to assays developed under the agreement and will provide Gentris with certain payments resulting from the sale of such products (2/5) |
Genzyme | ImaRx | Agreement to evaluate the expression of Genzyme's nonviral gene therapy vectors in specific target tissues when combined with ImaRx's Aerosomes and Fluorogene microbubbles and Sonoporation | Financial terms were not disclosed (1/16) |
Genzyme | Genzyme | Agreement for rights to intellectual property and licenses related to cancer diagnostics | Genzyme Genetics paid $32M for the rights; Genzyme Molecular could receive another $1M in milestone payments (1/3) |
Geron Corp. | Genetic | Agreement giving GTI nonexclusive rights to Geron's human telomerase promoter for the development of therapeutic products targeting cancer | GTI will pay Geron a license fee, milestone payments and royalties on product sales (1/7) |
Geron Corp. | Lynx Thera- | Agreement in which Geron acquired Lynx's patents relating to oligonucleotides containing phosphoramidate backbone linkages | Geron paid $2.5M in cash and stock for the intellectual property; Geron will own patent rights to composition-of-matter and production process technologies for phosphoramidate oligonucleotides and related derivatives, including a manufacturing process for Geron's telomerase inhibitor GRN163 (3/6) |
Gradipore | Biomira Inc. | Agreement for the separation and purification of recombinant proteins based on Gradipore's platform separations technology, Gradiflow | Biomira will use Gradiflow to establish methods for isolating and purifying certain recombinant proteins; the agreement provides for the payment of certain performance-based fees to Gradipore (2/11) |
Graffinity | Structural | Collaboration aimed at creating an approach for more rapid lead discovery | Graffinity will screen several targets, supplied by SGX, with its library of small molecular fragments; Graffinity will synthesize selected fragments and SGX will co-crystallize a combination of selected fragments with the targets and provide precise images of the interaction topology and binding modes (12/18) |
Gryphon | Avecia Bio- | Alliance designed to develop and ultimately supply Gryphon's performance-enhanced protein therapeutics | Gryphon has identified a number of chemically synthesized protein therapeutics that it will scale-up with Avecia (2/11) |
High Through- | Genometrix | Agreement in which High Throughput purchased all rights and interest in universal array intellectual property and tangible assets | High Throughput said the purchase complements its generic array intellectual property, strengthening and broadening its patent position (2/7) |
Human Genome | Cambridge Antibody Technology Group plc (UK; | Agreement for exclusive development on a human monoclonal antibody against cancer | Human Genome Sciences exercised an option for the agreement; the collaboration, announced in March 2000, is potentially worth $67M (1/8) |
Hybrigenics SA | Mindsense Biosystems Ltd. (Israel)* | Collaboration to identify biomarkers and drug targets for the diagnosis and possible treatment of depression | Hybrigenics will apply its high-throughput functional proteomics technologies to identify proteins that interact with a selection of Mindsense's targets in the area of mental disorders (2/1) |
Hyseq Pharma- | Amgen Inc. | Agreement in which Hyseq purchased Amgen's afimeprase | Hyseq will now control the compound's development, while Amgen will handle manufacturing; Amgen has the option to lead any commercialization of the product (1/9) |
IDEC Pharma- | ExonHit Thera- | Collaboration and research agreement for the discovery of antigen targets in antibody therapy, including prostate carcinoma | IDEC now has exclusive worldwide rights to certain antibody-based therapeutic applications of new target discoveries; ExonHit will receive an up-front payment, potential milestones and royalties on approved products (1/7) |
Illumina Inc. | Amersham Bio- | Agreement granting Illumina a nonexclusive worldwide license under five fundamental patents involving engineering designs and methods for confocal scanning | Illumina will use the designs and methods with its BeadArray product line (2/20) |
Illumina Inc. | Oxagen Ltd. | Collaborative commercial agreement to generate maps of single nucleotide polymorphism clusters in defined chromosomal regions | Oxagen will provide a collection of SNP loci within linkage regions together with samples from its library of family collection material and information; Illumina will use its BeadArray technology to design functional assays for the SNPs provided and generate several million overall genotype calls from the sample set; Oxagen will retain rights to all genes and novel associations discovered as a result of the study (3/20) |
Immunex Corp. | Genesis Research and Development Corp. Ltd. (New Zealand)* | Three-year agreement to research and develop selected molecules, as well as provide molecular biology and other research services to each other | No further details were disclosed (2/7) |
ImmunoGen | Millennium Pharmaceuticals | Exclusive product license agreement for use of ImmunoGen's maytansinoid tumor-activated prodrug technology with Millennium's MLN591 antibody | The agreement triggers Millennium's payment of a product-licensing fee to ImmunoGen (2/20) |
Incellico Inc. | Beyond | Agreement for Incellico's CELL ontological database platform | BG will add CELL to its suite of bioinformatics tools and will use it to help link together experimental and archived databases of genomic, proteomic and metabolic data (3/7) |
Incyte Genomics | Cambridge | Agreement that gives CAT access to the Incyte Life-Seq Gold database and options for product development rights | CAT will receive access to high-quality, sequence-verified human cDNA clones and rights to use this information for therapeutic antibody product development; CAT will pay a license fee, plus milestones and royalties for products developed (12/19) |
InforMax Inc. | TissueInformatics | Collaboration to integrate quantitative tissue data with genomic data | The companies will apply quantitative histomophometric data derived from digital tissue images in conjunction with gene expression and protein function data to understand the molecular toxicological effects of pharmaceutically relevant compounds; they also will collaborate on the development and validation of software tools to integrate and analyze tissue and genomic data (1/24) |
Inhale | Pharmacia Corp. | Collaborations for use of Inhale's PEG injectable technology | The agreements include up-front, milestone, royalty and manufacturing payments; Pharmacia will use the technology to advance its studies of CDP870 in both rheumatoid arthritis and Crohn's disease; 3DP will use it for its synthetic thrombopoietin mimetic compound (3DP-3534) to treat low blood platelet count; and Eyetech will use the technology with EYE001 to treat age-related macular degeneration (2/26) |
Inhale | Unimed Pharma- | Collaboration for use of Inhale's pulmonary technology | The agreement includes up-front, milestone, royalty and manufacturing payments; Inhale will have responsibility for development of dronabinol, the active ingredient in Marinol, as well as clinical and commercial manufacturing of the drug formulation and inhaler combination; Unimed will be responsible for clinical development and worldwide commercialization of the system (2/26) |
Insmed Inc. | Oxagen Ltd. | Collaborative research agreement to investigate the genetic profile associated with polycystic ovary syndrome and other metabolic disorders related to insulin resistance | Insmed will have the rights to use the research results to develop drug targets and therapeutics for the prevention and treatment of the disease; Oxagen may, at its option, co-develop novel targets with Insmed and retains rights to diagnostic applications involving the detection of predisposition to PCOS or prediction of therapeutic response (2/19) |
Intradigm | DirectGene | Collaborative research and development agreement in which the companies will work to generate cancer drugs | They will develop systemically delivered, mechanism-directed cancer therapies using nucleic acid delivery technology (1/25) |
Introgen | Biogen Inc. | Multiyear agreement to provide process development and manufacturing services for therapeutic gene delivery systems | Introgen will generate materials and make recommendations to support Biogen's product development activities in gene therapy (1/15) |
Ionix Pharma- | Evotec OAI | Agreement to collaborate on the design and synthesis of drug-like chemical compounds for evaluation as potential inhibitors of an Ionix drug target | Ionix will own, develop and commercialize drug candidates that derive from the collaboration; Evotec will receive program funding, and downstream payments for successful development and commercialization of product candidates (2/5) |
Ionix Pharma- | Xenome Ltd. | Agreement to collaborate on the design, synthesis and screening of toxins and derivatives for evaluation as potential inhibitors of Ionix drug targets | The collaboration includes the search for selective antagonists of a sodium channel drug target that is expressed in the PNS; the companies also will collaborate on the use of their computational chemistry, medicinal chemistry and pharmacology resources to design and evaluate lead series of both peptide and nonpeptide drugs arising from their research (3/5) |
Isis Pharma- | Amgen Inc. | Agreement in which Isis' GeneTrove division entered a functional genomics alliance with Amgen | Amgen gains access to Isis' antisense gene functionalization target validation expertise and to specific patents within Isis' functional genomics suite of patents (1/3) |
Isis Pharma- | Eyetech Pharm- | Intellectual property licensing agreement for Isis' patents necessary for Eyetech to develop, make and commercialize EYE001, a non-antisense compound for the treatment of ophthalmic diseases | Eyetech will pay Isis up-front fees and milestone and royalty payments in the multimillion-dollar transaction in exchange for nonexclusive, worldwide rights to the intellectual property licensed from Isis (1/7) |
Lynx Thera- | Keryx Bio- | Agreement to provide immunological research services aimed at profiling the biological activity of several of Keryx's compounds on immune cells | The services will be provided through Lynx's wholly owned subsidiary, Lynx Therapeutics GmbH (Germany); Lynx will receive payments from Keryx for immunology research services performed over the term of the agreement (2/5) |
Mabtech AB | Seattle Genetics | Agreement to license certain monoclonal antibodies | The agreement includes antibodies that target cell surface molecules on a variety of cancer cell types; Seattle Genetics has development, manufacturing and worldwide commercialization rights to therapeutic products derived from the antibodies (3/14) |
Maxygen Inc. | Celltech Group | Agreement to apply Maxygen's Molecular Breeding directed evolution technology to four Celltech monoclonal antibody programs | Maxygen may receive license and option fees, full research and development funding, milestone payments and royalties on product sales; Celltech retains exclusive worldwide rights to commercialize antibody therapeutics developed (1/8) |
Medarex Inc. | Sangamo | Agreement to boost antibody expression in mammalian cell lines using Sangamo's DNA-binding protein gene regulation platform | Medarex will provide two years of research funding and will hold a nonexclusive license to use the cell lines created; Sangamo gets unspecified milestone payments plus royalties (1/9) |
Medarex Inc. | Tularik Inc. | An applied genomics deal in which Medarex will use its UltiMab Human Antibody Development System to generate fully human antibodies based on three novel oncogenes discovered by Tularik | The two companies are 50-50 partners on the development of products (1/9) |
Medarex Inc. | Zycos Inc.* | Partnership to discover cancer drugs using technologies developed by each company | Medarex will contribute its UltiMAb Human Antibody Development System to generate the antibodies against targets identified from Zycos' protein expression screening technology, named Canvas; the deal is a 50-50 arrangement (1/22) |
MetaGen | InforSense | Agreements giving MetaGen additional information technology to accelerate and validate in-house data mining processes | InforSense will provide MetaGen with Kensington Discovery Edition, a discovery software platform; MetaGen will use it for the interactive analysis of large data sets; InforSense will create and integrate features that arise from the companies' interaction (3/1) |
Millennium | Paion GmbH | Collaboration on MLN519 to treat stroke and certain other neurological conditions | Paion will be responsible for the compound's development, including all costs; Millennium retains exclusive commercial rights in North America and parts of Asia, and would receive royalties on European sales, in addition to milestone payments; Paion has rights in Europe and certain Asian countries, for which Millennium will receive option payments; Paion will receive royalties in all other major markets (3/14) |
Mixture Sciences | HeptaHelix | Research collaboration to use Mixture's mixture-based combinatorial libraries to identify ligands for HeptaHelix's collection of G protein-coupled receptors using its reporter analysis, a biosensor system | Mixture will provide a variety of mutually selected mixture-based combinatorial libaries; Mixture and HeptaHelix will use these libraries to identify ligands for a a variety of mutually selected cell-based reporter-gene systems, including G protein-coupled and orphan receptors (2/15) |
MPB Cologne | BioSecure | Agreement for a feasibility study on growing potato minitubers containing pharmaceutical proteins | A series of chambers will be constructed by BioSecure using its GroWmax technology to establish production of minitubers supplied by MPB Cologne (3/12) |
|
Neurotech SA (France)* |
Amgen Inc. (AMGN) | License agreement for the right to develop and market ciliary neurotrophic factor in local delivery of ophthalmology indications | Neurotech also was granted an exclusive license from the Regents of the University of California under a patent claiming the use of CNTF in degenerative eye disease (1/14) |
N-Gene | Allos Thera- | Licensing agreement to intellectual property surrounding BGP-15 in contained-environment growth chambers | Allos intends to develop the compound as the first orally available chemotherapy protectant capable of reducing or eliminating the need for supportive care therapy; Allos will acquire development and exclusive marketing rights for BGP-15 in the U.S.; Allos will make an initial equity investment in N-Gene, subsequent equity investments and licensee payments based on development milestones; it also will pay royalties (3/12) |
Norak Bio- | Universal | Collaboration to enable biotechnology and pharmaceutical companies involved in drug discovery to study G protein-coupled receptors in high-content modes | The companies will combine two new screening technologies; financial terms were not disclosed (1/2) |
OmniScience | Ibis Thera- | Research collaboration for the discovery and development of new compounds | OmniScience will receive an up-front payment, potential milestone payments, and royalties on any product sales (2/14) |
Onyx Pharma- | Proacta | Agreement to evaluate and potentially develop cancer therapeutics | Onyx will provide the therapeutic viruses to Proacta, which will conduct all research activities; based on the results, the companies may enter a further collaboration or license agreement to develop a nitroreductase-armed virus product (3/5) |
Orchid Bio- | Asper Biotech | Agreement granting Asper a nonexclusive license to Orchid's SNP-IT primer extension SNP scoring technology for use in a slide-based array format targeted to the research market | Orchid will receive an up-front payment and royalties on sales (1/24) |
Orchid Bio- | First Genetic | Alliance to develop and market a range of pharmaco-genetic services to pharmaceutical and biotechnology companies, academic research centers and health care providers | First Genetic Trust will provide its genomic data banking services, clinical trial management capabilities and collaborative patient registries to the alliance, while Orchid offers high-throughput genotyping services and associated analytic and data support; Orchid and First Genetic will collaborate to develop and market a variety of services (3/5) |
Orchid Bio- | Thermo | Technology agreements to develop and market next-generation genotyping products for research and pioneering SNP-based point-of-care diagnostic tests | Orchid obtains nonexclusive rights from the Thermo BioStar division to develop, supply and sell genotyping products for the research market, combining Orchid's SNP-IT genotyping and Thermo BioStar's OIA and thin-film biosensor technologies (2/7) |
Oxford Gene | Arrow Thera- | Agreement for Arrow to acquire OGT's DNA micro-array business | The deal includes a license to OGT's patents and was largely funded in Arrow shares (1/14) |
Oxford Glyco- | GeneProt | Licensing agreement for two of Oxford's automated proteomics patents | Oxford will receive an up-front fee of $1M and undisclosed annual payments (2/13**) |
Pharmacopeia | Locomogene | Research collaboration in the osteoarthritis/rheumatoid arthritis area | Pharmacopeia will provide assay development expertise, a compound sample collection and ultra-high-throughput screening technology to identify lead compounds for a Locomogene target (12/18) |
Phytomedics | Degussa Bio- | Agreement to co-develop, produce and market PMI-5011 | Terms were not disclosed (1/22) |
Phytomedics | Eisai Research | Agreement to discover therapeutic compounds for use in cancer therapy | Financial details were not disclosed (2/12) |
Pieris | CytoTools | Agreement to discover human Anticalins based on Pieris' Anticalin technology against a number of CytoTools' targets implicated in atherosclerosis | CytoTools will receive an exclusive license to the Anticalins developed during the collaboration and Pieris will receive milestone payments and royalties (1/24) |
Prescient | Access Oncology | Licensing agreement for the anticancer compound, Anhydrovinblastine | Access now has exclusive rights to develop and market AVLB worldwide, except in Latin America and the Far East; Access will make up-front and early milestone payments of $1.25M and development milestone payments up to $17.5M; Access also will pay royalties on net sales and fund all further development of AVLB; Access has an option to purchase up to $5M of the last milestone in Prescient equity at a 50% premium to market at the time (1/8) |
PrimeGen | Agilon Products | Agreement intended to expand and strengthen PrimeGen's foothold in the stem cell and genetic research space | The companies also will accelerate the acceptance of PrimeGen's Cellular Replacement Therapy (2/27) |
Procyon | Chiron Corp. | Agreement for an evaluation of the Prostate Secretory Protein technology being developed initially for the treatment of late-stage prostate cancer | Terms include an exclusive period of six months for the evaluation of the program, which encompasses applications of the recombinant PSP94 peptide as well as the synthetic peptide PCK3145 (1/9) |
Protein Design | Celltech Group | Nonexclusive license for humanized antibodies against tumor necrosis factor-alpha (TNF-a), believed to be an important factor in the inflammatory process in humans | The license was granted under the terms of an agreement announced in January 2000 covering certain intellectual property in the field of humanized antibodies, and triggers payment of an additional license fee to PDL (12/20) |
Ricerca LLC* | Genset SA | Licensing agreement for the RAP-3 gene | Genset plans to start an oncology program that uses the gene as a drug target and possibly as a protein therapeutic; the deal includes milestone payments (3/12) |
Ricerca LLC* | Gvk bioSciences | Small-molecule drug discovery and development partnership | Gvk will build a new facility to do medicinal chemistry and biology under Ricerca's direction for client drug discovery programs and lead optimization of each company's own drug targets; Gvk will license to Ricerca its bioinformatics tools in exchange for access to Ricerca's ADMET and related pharmaceutical data (2/19) |
Sicor Inc. | EPIC Thera- | Licensing and development agreement involving a depot formulation (LeuPro-Maxx) of leuprolide acetate formulated to be clinically equivalent to Lupron Depot | Sicor and EPIC intend to develop additional compounds over the contract term to further capitalize on EPIC's technology (12/20) |
SignalGene | ArQule Inc. | Agreement in which the companies are applying their prototype computational compound design technology to ArQule's p38 MAP kinase drug discovery program | ArQule will make and test selected compounds for biological activity against p38 MAP kinase and has development rights for any resulting lead compounds; SignalGene will receive research fees and additional milestone payments (2/21) |
Silico Insights | Genzyme | Collaboration to identify and characterize oncogenic pathways and new drug targets with an initial focus on breast cancer | The companies will use data from Genzyme Molecular Oncology's SAGE database in combination with Silico's pathway elucidation platform (2/6) |
Structural | Millennium | Agreement in which Structural GenomiX will use its technology to generate large-scale structural information for Millennium drug targets | Structural GenomiX will focus on structural information from Millennium targets and co-crystallization with lead compounds, and the second will focus on using further structural analysis of a smaller number of certain target families to determine proteins that are closely related to the drug targets; Millennium will make an equity investment in Structural GenomiX (1/7) |
Synt:em | Corixa Corp. | Nonexclusive agreement designed to develop vaccines based on Corixa's antigens aimed at infection prophylaxis and cancer therapy | Synt:em will contribute its Pep:trans technology; it has received license fees and has the potential for milestones and royalties, along with a share of any sublicense income that Corixa receives for vaccines using Pep:trans vectors (3/11) |
Syn-X Pharma | Undisclosed life sciences company | A standstill agreement giving the undisclosed company rights for 30 days to negotatiate and enter an agreement with Syn-X for a license and supply agreement to Syn-X's method for the detection and measurement of human brain glutamine synthetase and associated reagents | Syn-X will receive a nonrefundable payment in consideration for entering the standstill agreement (2/1) |
Syrrx Inc.* | Metaphorics | Research collaboration to improve computational tools for docking ligand molecule structures into protein binding sites | The companies expect to create new software to improve the ability to predict the potential complements between ligands and proteins (2/28) |
Third Wave | Daiichi Pure | Collaboration under which Third Wave will develop and supply to Daiichi a series of Invader genetic analysis products for the development of personalized cancer treatments | Daiichi will use the Invader products in clinical trials to validate known associations of patient predisposition to side effects from irinotecan (1/18) |
Valentis Inc. | Genzyme Corp. | Nonexclusive cross-licensing agreement in which Genzyme receives rights to Valentis' GeneSwitch gene regulation technology for research use and Valentis receives certain rights to Genzyme's plasmid DNA manufacturing technology | Genzyme plans to use GeneSwitch for its internal product research (1/9) |
Variagenics Inc. | GeneMatrix | Research and development collaboration to develop molecular diagnostic products for predicting response to leading drugs in the treatment of colon and gastric cancer | They will collaborate on pharmacogenomic research and clinical development of targeted therapeutics (12/20) |
Vical Inc. | CytRx Corp. | Exclusive, worldwide license agreement granting Vical rights to CytRx's TranzFect poloxamer technology to enhance viral or nonviral delivery of polynucleotides in all human and animal health applications, except four infectious disease vaccine targets and prostate-specific membrane antigen | Vical will make an up-front payment and CytRx will have the opportunity for milestones and royalties (12/18) |
ViroLogic Inc. | Achillion Pharm- | Agreement to use ViroLogic's drug-resistance assays to evaluate Achillion's lead product candidate, ACH-126,443, to treat hepatitis B and HIV | Financial terms were not disclosed (2/7) |
ViroLogic Inc. | Panacos Pharm- | Agreement to use ViroLogic's drug-resistance assays in the preclinical evaluation of Panacos' lead HIV drug candidates, PA-344B and PA-457 | Panacos plans to advance PA-344B into clinical studies this year; financial terms of the agreement were not disclosed (2/12) |
Xenogen | Chiron Corp. | Commercial licensing agreement for real-time in vivo imaging technology, granting Chiron access to Xenogen's suite of technologies for use in preclinical drug development studies | Xenogen will receive an annual fee and the agreement is renewable after its second year (1/16) |
Xenon | Discovery | Drug discovery agreement to identify small-molecule compounds active against a Xenon-discovered metabolic disease target | Financial details were not disclosed (1/7) |
Xerion Pharma- | Procorde GmbH | Target validation collaboration with the initial focus on a cardiovascular target protein | Xerion plans to validate the protein's function by knocking it out; upon positive validation, Xerion plans to generate potential therapeutic antibodies against the target (2/6**) |
XOMA Ltd. | MorphoSys AG | Agreement for antibody-related technologies | XOMA will receive a license to use MorphoSys' HuCAL Gold antibody library for target discovery and research for five years, as well as license payments, and MorphoSys and its partners receive a license to use XOMA antibody expression technology for developing antibody products using MorphoSys' phage display-based HuCAL antibody library (2/25) |
Zyomyx Inc.* | Specialty | Agreement granting Specialty early access to Zyomyx's Protein Profiling Biochip platform | Zyomyx will collaborate with Specialty on a diagnostic marker discovery program (2/26) |
| |
|||
Notes: |
|||
# This chart does not include agreements that involve agricultural product development. |
|||
* Private companies are indicated with an asterisk. |
|||
** Denotes the date the item ran in BioWorld International. |
|||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. |
|||
ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange |
|||
